<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168050</url>
  </required_header>
  <id_info>
    <org_study_id>P081237</org_study_id>
    <nct_id>NCT01168050</nct_id>
  </id_info>
  <brief_title>Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.</brief_title>
  <acronym>NILOMEL</acronym>
  <official_title>Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of&#xD;
      Nilotinib in first or second line treatment of primary melanomas , stage III unresectable&#xD;
      melanomas, or Stage IV melanomas with c-KIT mutation or amplification. The primary objective&#xD;
      is overall response rate (partial and complete response) according to RECIST 1.1 criteria,&#xD;
      assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months&#xD;
      therapy with Nilotinib 800 mg/d. Secondary objectives include:&#xD;
&#xD;
        -  Disease control rate (complete, partial response and stable disease)&#xD;
&#xD;
        -  Metabolic response&#xD;
&#xD;
        -  Tolerance NCI CTCAE Version 3.0&#xD;
&#xD;
        -  Biomarkers associated to response and disease control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of&#xD;
      Nilotinib in first or second line treatment of primary melanomas , stage III unresectable&#xD;
      melanomas, or Stage IV melanomas with c-KIT mutation or amplification (in case of c-KIT&#xD;
      amplification, no B-RAF nor N-Ras mutation should be detected). The primary objective is&#xD;
      overall response rate (partial and complete response) according to RECIST 1.1 criteria,&#xD;
      assessed using CT-SCAN (stage IV melanoma) or MRI (unresectable melanoma) after 6 months&#xD;
      therapy with Nilotinib 800 mg/d. Secondary objectives include:&#xD;
&#xD;
        -  Disease control rate (complete, partial response and stable disease) according to RECIST&#xD;
&#xD;
        -  Metabolic response rate (TEP-SCAN)&#xD;
&#xD;
        -  Tolerance NCI CTCAE Version 3.0&#xD;
&#xD;
        -  Biomarkers associated to response and disease control (evaluated at M0, M1 and M6).&#xD;
           Protein analysis of c-KIT, PI3K, MAPK and STAT signalling pathways as well as PDGFR and&#xD;
           Ephrin signalling pathways.&#xD;
&#xD;
      Patients with progressive disease after 3 months therapy will be withdrawn. Patient with&#xD;
      stable disease after 3 months will continue Nilotinib until evaluation at 6 months. Patients&#xD;
      with stable disease or progressive disease at 6 months will continue Nilotinib until&#xD;
      progression.&#xD;
&#xD;
      The trial has been planned using a one-stage design (Fleming TR) . We considered that a&#xD;
      response rate under 7.5% would define the null hypothesis of no efficacy . To detect a&#xD;
      response rate of 30% or more with power 90% using a one-sided test at the 0.05 level, 25&#xD;
      patients have to be recruited.&#xD;
&#xD;
      Accrual for 2.5 years total study duration: 3 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response</measure>
    <time_frame>6 months</time_frame>
    <description>Partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control</measure>
    <time_frame>6 months</time_frame>
    <description>Complete or partial response or stable disease per Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>3 months</time_frame>
    <description>Partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic response</measure>
    <time_frame>6 months</time_frame>
    <description>Metabolic response as evaluated by TEP-SCAN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>1 year</time_frame>
    <description>Tolerance will be evaluated according to National Cancer Institute (NCI) Criteria for Adverse Events, CTCAE v3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Malignant Skin Melanoma T0</condition>
  <condition>Stage III Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <condition>Amplification</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Nilotinib 400 mg twice per day</description>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically proven melanoma with either c-KIT mutation or C-KIT&#xD;
             amplification (without BRAF or NRAS mutation)&#xD;
&#xD;
          -  Unresectable primary or stage III or stage IV melanoma&#xD;
&#xD;
          -  Measurable disease (RECIST)&#xD;
&#xD;
          -  The inclusion of patients with primary tumor or metastasis accessible to sequential&#xD;
             biopsies will be favored. If such lesions are present, biopsies are mandatory and not&#xD;
             optional&#xD;
&#xD;
          -  No more than 1 previous specific therapy excluding tyrosine kinase inhibitors. 4 weeks&#xD;
             wash out will be needed after cytotoxic therapy , 12 weeks wash out after anti -CTLA4&#xD;
             therapy or any immunological treatment&#xD;
&#xD;
          -  No radiotherapy within 4 weeks ; previously irradiated lesion will not be considered&#xD;
             as measurable unless progression at inclusion&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  PNN ≥ 1,500/mm³ (G-CSF allowed)&#xD;
&#xD;
          -  platelets ≥ 100,000/mm³&#xD;
&#xD;
          -  Hb ≥ 9.0 g/dL ( transfusions allowed as well as recombinant erythropoetin)&#xD;
&#xD;
          -  Creatinin clearance &gt; 40ml/mn&#xD;
&#xD;
          -  Normal kalemia&#xD;
&#xD;
          -  Normal magnesemia&#xD;
&#xD;
          -  Total bilirubin &lt;1.5N ; ASAT and ALAT &lt;2.5N&#xD;
&#xD;
          -  PT/INR and PTT normal&#xD;
&#xD;
          -  NYHA class &lt; 3&#xD;
&#xD;
          -  Signed Written Informed Consent&#xD;
&#xD;
          -  Affiliated to the National Health Insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refusal&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Fertile women who do not want or cannot use effective contraception during the study&#xD;
             and up to 8 weeks after the end of study&#xD;
&#xD;
          -  Women pregnant or nursing&#xD;
&#xD;
          -  Women with positive pregnancy test at inclusion or before treatment initiation&#xD;
&#xD;
          -  Fertile and sexually active men whose partner are fertile women who do not use&#xD;
             effective contraception&#xD;
&#xD;
          -  Clinical and/or radiographic evidence of active cerebral metastases&#xD;
&#xD;
          -  Severe evolutive infection&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Concomitant therapy with any other anti-cancer, immunomodulator or immunosuppressing&#xD;
             agent or radiotherapy (except palliative care if bone metastases, after acceptance of&#xD;
             principal investigator).&#xD;
&#xD;
          -  Previous use of tyrosine kinase inhibitors&#xD;
&#xD;
          -  More than one line of prior systemic therapies of melanoma by anti-cancer agent or&#xD;
             immunotherapy.&#xD;
&#xD;
          -  Received experimental treatment within 4 weeks of inclusion&#xD;
&#xD;
          -  Pace-maker&#xD;
&#xD;
          -  Cardiac dysfunction, as evaluated by one of:&#xD;
&#xD;
               -  Ejection fraction &lt; 45% (less than 28 days from inclusion)&#xD;
&#xD;
               -  Congenital prolonged QT&#xD;
&#xD;
               -  QTc &gt; 450 ms&#xD;
&#xD;
               -  Ventricular tachyarrhythmia within the past 6 months&#xD;
&#xD;
               -  Bradycardia at rest &lt; 50/mn&#xD;
&#xD;
               -  Major conduction dysfunction&#xD;
&#xD;
               -  Myocardial infarction within the previous 6 months&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Digestive disease that may inhibited NILITINIB absorption&#xD;
&#xD;
          -  Concomitant medication that may increase QT&#xD;
&#xD;
          -  Taking CYP3A4 inhibitors&#xD;
&#xD;
          -  Eating Sevilla oranges (or Sevilla oranges derivates), grapefruit (or grapefruit&#xD;
             juice), grapes (or grapes juice), pomegranate (or pomegranate juice)&#xD;
&#xD;
          -  Hereditary galactose intolerance, Lapp-lactase deficiency or glucose-galactose&#xD;
             malabsorption.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celeste Lebbe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Louis, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zakia Idir, PhD</last_name>
    <phone>+33 1 4484 1747</phone>
    <email>zakia.idir@sls.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Lebbe, MD, PhD</last_name>
      <email>celeste.lebbe@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Celeste Lebbe, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <last_update_submitted>February 7, 2011</last_update_submitted>
  <last_update_submitted_qc>February 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Zakia Idir</name_title>
    <organization>Department Clinical Research of Developpement</organization>
  </responsible_party>
  <keyword>Malignant Skin Melanoma T0</keyword>
  <keyword>stage III unresectable melanomas,</keyword>
  <keyword>or stage IV melanomas with c-KIT mutation</keyword>
  <keyword>or amplification.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

